Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from BioNTech

Pfizer-BioNTech Seek US Approval of Second Covid Booster for 65+

Pfizer and BioNTech announced Tuesday they had formally asked the United States drug regulator for emergency approval of a second booster shot of their Covid vaccine for people aged 65 and older. The companies said in a press statement that their request is based off two Israeli studies that show…

Asharq Al-Awsat

Pfizer and BioNTech plan to seek authorization for second COVID booster for people 65 and up

The move is an attempt to bolster waning immunity that occurs several months after a first booster shot.

Axios

Here's Why BioNTech Shares Are Rising On Monday

BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by 14.8% at $155.65. Strength is possibly due to a spike in COVID-19 cases in China, which could lift vaccine sector sentiment.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

How drug companies are sidestepping the WHO's technology transfer hub in Africa

Pharmaceutical company Moderna announced on 7 March 2022 that it would develop a site in Kenya to manufacture COVID-19 vaccines. The company holds much of the key intellectual property relating to the messenger RNA (mRNA) vaccines. Due to their higher efficacy, mRNA vaccines are the preferred option in developed countries.…

The Conversation

BioNTech, Regeneron To Evaluate FixVac-Based Cancer Vaccine/Libtayo Combo In NSCLC

BioNTech SE (NASDAQ:BNTX) has expanded its strategic collaboration with Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to its FixVac candidate BNT116 combined with Libtayo (cemiplimab) in advanced non-small-cell lung cancer (NSCLC). Under the terms of the agreement, the companies plan to jointly conduct clinical trials to evaluate the combination in different patient populations with advanced NSCLC and share…

Benzinga

Where BioNTech Stands With Analysts

BioNTech (NASDAQ:BNTX) has observed the following analyst ratings within the last quarter:

Benzinga

BioNTech, Medigene Ink Immunotherapy Pact Against Cancer

BioNTech SE (NASDAQ: BNTX) and Medigene AG have entered a multi-target research collaboration to develop T cell receptor (TCR) based immunotherapies against cancer.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Pfizer/BioNTech's Omicron-Targeted COVID-19 To Miss March Timeline: Reuters

Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) omicron-targeted COVID-19 vaccine is delayed by several weeks due to a slower-than-expected data gathering process,

Benzinga

This Reopening Stock Has A Better 1-Year Return Than Moderna, Pfizer, BioNTech, Novavax And Vaxart

Macy's Inc (NYSE: M) retail stores have something for everyone in the family, and over the past year, has returned unmistakable gains for bullish traders and investors.

Benzinga

BioNTech Unveils First Modular mRNA Manufacturing Facility In Africa

BioNTech SE (NASDAQ: BNTX), which developed the first widely approved COVID-19 shot together with Pfizer Inc (NYSE: PFE),

Benzinga

BioNTech Pledges African Access to its Future Cancer Drugs

Germany's BioNTech, which is preparing to produce its COVID-19 vaccine or other disease-preventing shots in Africa, said that novel cancer therapies it is working on will in future be available on the continent at affordable prices. "We pledge as BioNTech to develop our cancer medicines also according to the needs…

Asharq Al-Awsat

BioNTech plans modular vaccine factories in Africa

German vaccine maker BioNTech unveiled plans Wednesday to establish manufacturing facilities in Africa that would boost the availability of much-needed medicines on the continent

The Independent UK

Why BioNTech Shares Are Falling Today

BioNTech SE (NASDAQ: BNTX) is trading lower Monday morning after the U.S. Food and Drug Administration (FDA) requested additional data before approving its COVID-19 vaccine for children aged six months to four years old.

Benzinga

Pfizer accused of pandemic profiteering as profits double

Drugmaker makes $37bn in vaccine sales and predicts bumper year ahead from Covid jabs and pill

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

Asharq Al-Awsat

Pfizer Seeks US Approval of Covid Vaccine for Children under 5

Pfizer and BioNTech said Tuesday they are seeking emergency authorization from US health regulators for use of their Covid vaccine for children aged over six months and under five years. If the Food and Drug Administration (FDA) authorizes the two-shot regimen, it will become the first Covid vaccine available to…

The Guardian - AU

Covid news: Anger as Tory MP says lockdown breach ‘like parking fine’; Germany could relax restrictions in March – as it happened

Pfizer-BioNTech seeks US approval for under-5s Covid inoculation; Lithuania to scrap Covid pass on Saturday

Benzinga

Pfizer Could Seek COVID-19 Vaccine Emergency Approval For Children Under 5 This Week

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) are likely to submit a request for an emergency use authorization to the U.S.

StockNews.com

Down Close to 40% Year-To-Date, Now is a Good Time to Scoop Up Moderna and BioNTech

The ongoing market correction has caused the shares of popular vaccine makers Moderna (MRNA) and BioNTech (BNTX) to decline nearly 40% in price so far this year. However, because the demand for COVID-19 vaccines remains strong globally, these companies are expected to generate substantial revenues and profits in the coming…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

What Are Whales Doing With BioNTech

Someone with a lot of money to spend has taken a bearish stance on BioNTech (NASDAQ:BNTX). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

ABC News

Anthony Fauci says Omicron-specific COVID-19 vaccine may be prudent but not needed, as clinical trials announced

A COVID-19 vaccine specifically targeting the Omicron variant would be "prudent", even if it ultimately may not be needed, the top US infectious disease official says, as Pfizer announces trials for such a vaccine.

Evening Standard

Pfizer and BioNTech launch clinical trial for Omicron-specific vaccine

Pfizer Inc and BioNTech have announced the start a clinical trial to test a new version of their vaccine specifically designed to target the Omicron variant of Covid-19 Omicron variant.

Tribune News Service

Pfizer, BioNTech begin study of omicron-specific COVID vaccine

Pfizer Inc. said it is starting a study of a COVID-19 vaccine that targets the omicron variant, exploring its use in previously vaccinated younger and middle-aged adults as well as those who haven’t received another coronavirus shot.

Benzinga

Pfizer, BioNTech Launch Omicron-Targeted COVID-19 Vaccine Trial

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have

Asharq Al-Awsat

Pfizer and BioNTech Launch Trial of Omicron-Targeted COVID Vaccine

Pfizer Inc and BioNTech SE said on Tuesday they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen. The companies plan to test the immune…

Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech Starts Omicron-Specific Vaccine Study, J&J Misses On Topline, Sierra Oncology Reports Positive Data

Here's a roundup of top developments in the biotech space over the last 24 hours.

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Office for National Statistics

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.